Minnesota Senate Bill SF1023

Minnesota 2025-2026 Regular Session

• Introduced: 2/6/25
• Refer: 2/6/25

Caption

Inherited metabolic diseases coverage by health plans requirement provision

Summary

SF1023 would require Minnesota health plans to cover medically necessary treatment for inherited metabolic diseases. The bill specifically includes coverage for medical foods and low-protein modified food products used under a physician’s direction, and it defines those terms in statute. It also bars health plans from applying special restrictions to this coverage, such as extra cost-sharing, prior authorization, utilization review, referral requirements, delays, or other limitations not generally imposed on comparable benefits. The bill extends the same coverage standard to Medical Assistance. It amends Minnesota Statutes, chapter 256B, to require Medicaid coverage of medically necessary treatment for inherited metabolic diseases, including medical foods and low-protein modified food products, and it ties Medical Assistance to the same requirements that would apply to private health plans under the new insurance coverage section. In effect, the bill creates a uniform coverage mandate across both private insurance and public health coverage for this category of rare metabolic disorders.

Impact

The bill would add a new insurance mandate in Minnesota Statutes chapter 62Q and amend section 256B.0625 to require Medical Assistance coverage for inherited metabolic disease treatment. It would affect health plans and Medicaid by requiring payment for medically necessary treatment, including specialized dietary products, and by limiting insurers’ ability to impose utilization management or other coverage barriers. The practical effect is to expand covered benefits for individuals with inherited metabolic diseases and to standardize coverage rules across private and public payers.

Sentiment

The available context suggests the bill was introduced as a targeted health coverage measure with no recorded committee testimony or votes in the provided materials. The authorship by multiple senators and the straightforward referral to the Commerce and Consumer Protection Committee indicate an initial level of legislative interest, but there is no evidence in the supplied record of formal support or opposition being expressed. Overall, the bill appears to have been presented as a specialized coverage expansion rather than a broadly controversial measure.

Contention

The main policy issue likely to draw scrutiny is the cost and scope of the mandate on health plans and Medical Assistance, especially because the bill requires coverage of medical foods and low-protein modified food products and prohibits common utilization controls. Insurers and budget-conscious policymakers may question whether these products should be treated as covered medical benefits and how much the mandate would increase premiums or public spending. Supporters would likely emphasize the medical necessity of these treatments for people with rare inherited metabolic diseases and the need to prevent coverage denials or delays.